Prudential Financial
RCUS icon

Prudential Financial’s Arcus Biosciences RCUS Stock Holding History

Prudential Financial’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.41M Buy
110,603
+22,630
+26% +$559K ﹤0.01% 1169
2026
Q1 		$1.9M Buy
87,973
+8,515
+11% +$184K ﹤0.01% 1327
2025
Q4 		$1.89M Buy
79,458
+9,193
+13% +$188K ﹤0.01% 1343
2025
Q3 		$956K Buy
70,265
+255
+0.4% +$2.65K ﹤0.01% 1673
2025
Q2 		$570K Buy
70,010
+4,275
+7% +$36.5K ﹤0.01% 1894
2025
Q1 		$516K Buy
65,735
+10,430
+19% +$121K ﹤0.01% 1825
2024
Q4 		$823K Sell
55,305
-600
-1% -$9.8K ﹤0.01% 1646
2024
Q3 		$855K Sell
55,905
-2,550
-4% -$40.2K ﹤0.01% 1967
2024
Q2 		$890K Sell
58,455
-4,850
-8% -$78.3K ﹤0.01% 1899
2024
Q1 		$1.2M Buy
63,305
+1,050
+2% +$18.2K ﹤0.01% 1733
2023
Q4 		$1.19M Sell
62,255
-13,920
-18% -$222K ﹤0.01% 1731
2023
Q3 		$1.37M Sell
76,175
-2,080
-3% -$41.8K ﹤0.01% 1601
2023
Q2 		$1.59M Buy
78,255
+14,273
+22% +$272K ﹤0.01% 1557
2023
Q1 		$1.17M Sell
63,982
-1,865
-3% -$35.6K ﹤0.01% 1661
2022
Q4 		$1.36M Sell
65,847
-245
-0.4% -$6.74K ﹤0.01% 1531
2022
Q3 		$1.73M Buy
66,092
+4,605
+7% +$122K ﹤0.01% 1418
2022
Q2 		$1.56M Buy
61,487
+38,140
+163% +$934K ﹤0.01% 1544
2022
Q1 		$737K Sell
23,347
-308
-1% -$10.3K ﹤0.01% 2019
2021
Q4 		$957K Sell
23,655
-175
-0.7% -$6.79K ﹤0.01% 1900
2021
Q3 		$831K Buy
23,830
+380
+2% +$11.8K ﹤0.01% 1912
2021
Q2 		$644K Sell
23,450
-21,081
-47% -$602K ﹤0.01% 2044
2021
Q1 		$1.25M Buy
44,531
+342
+0.8% +$11.9K ﹤0.01% 1708
2020
Q4 		$1.15M Sell
44,189
-16,980
-28% -$411K ﹤0.01% 1684
2020
Q3 		$1.05M Sell
61,169
-19,125
-24% -$427K ﹤0.01% 1622
2020
Q2 		$1.99M Buy
80,294
+55,914
+229% +$1.51M ﹤0.01% 1340
2020
Q1 		$338K Sell
24,380
-43,330
-64% -$539K ﹤0.01% 2028
2019
Q4 		$684K Buy
+67,710
New +$569K ﹤0.01% 1977

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Prudential Financial's RCUS Position: Q2 2026 in Review

Prudential Financial increased its Arcus Biosciences (RCUS) stake by 26% in Q2 2026, buying an estimated $559K and bringing the position to 110,603 shares worth $3.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1169.

Prudential Financial first reported a position in RCUS in Q4 2019 and has held it in 27 quarters since. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Prudential Financial held 110,603 shares of Arcus Biosciences worth $3.41M as of Q2 2026.
  • Prudential Financial bought 22,630 Arcus Biosciences shares in Q2 2026, an estimated $559K.
  • Arcus Biosciences made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #1169 holding.
  • Prudential Financial first reported a position in Arcus Biosciences in Q4 2019 and has held it in 27 quarters since.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.